- Q2 2023 Think Research Corporation Earnings Call TranscriptAug 29, 2023C$0.31 (+6.90%)Earnings
- Q1 2023 Think Research Corporation Earnings Call TranscriptMay 30, 2023C$0.35 (+9.37%)Earnings
- Q4 2022 Think Research Corporation Earnings Call TranscriptMay 01, 2023C$0.35 (-18.60%)Earnings
- Think Research Corporation at Bloom Burton & Co Healthcare Investor Conference TranscriptApr 26, 2023
- Q3 2022 Think Research Corporation Earnings Call TranscriptNov 28, 2022C$0.32 (-8.57%)Earnings
- Q2 2022 Think Research Corporation Earnings Call TranscriptAug 29, 2022C$0.66 (-12.00%)Earnings
- Think Research Corporation at GCFF Global Chinese Financial Conference -- Healthcare Investment North America (Virtual) TranscriptJun 16, 2022
- Q1 2022 Think Research Corporation Earnings Call TranscriptMay 30, 2022C$0.7 (+4.48%)Earnings
- Think Research Corporation at Bloom Burton & Co. Healthcare Investor Conference TranscriptMay 03, 2022
- Q4 2021 Think Research Corporation Earnings Call TranscriptMay 02, 2022C$0.8 (-4.76%)Earnings
- Think Research Corporation SNN Network Webcast TranscriptDec 30, 2021
- Think Research Corporation at Desjardins Digital Healthcare Conference (Virtual) TranscriptNov 30, 2021
- Q3 2021 Think Research Corporation Earnings Call TranscriptNov 29, 2021C$1.57 (+3.29%)Earnings
- Q2 2021 Think Research Corporation Earnings Call TranscriptAug 23, 2021Earnings
Think Research Corporation at Desjardins Digital Healthcare Conference (Virtual) Transcript
Good afternoon. Welcome back. My name is David Newman, Desjardins diversified industries analyst covering the healthcare tech industry. I welcome to our next session with Think Research, joined by Sachin Aggarwal, CEO, and Jae Cornelssen, CFO. We have a buy on the stock and a $4 target price.
Think is driving solutions across the healthcare backbone, spanning knowledge, research, connectivity, and services. Its tools are being used to organize medical knowledge and patient data, reduce healthcare costs, and improve, most importantly, healthcare outcomes. It's a SaaS-driven, highly predictable model, focus on B2B and B2G. It's been a -- they've been busy on the acquisition front with the recent BioPharma and Pharmapod acquisitions.
Sachin and Jae, welcome, and thank you for joining this for the first time this year. So, welcome, and over to you for some opening comments.
Yeah. And thanks, David, for having us. This is always a real pleasure to be working
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)